keyword
https://read.qxmd.com/read/38530748/htlv-in-sweden
#21
JOURNAL ARTICLE
Jan Vesterbacka, Anna-Karin Svensson, Piotr Nowak
Sweden is a country with a low prevalence of human lymphotropic T-cell virus (HTLV) infection, estimated at < 0.005%, but the infection rate is notably higher in specific risk groups such as HTLV-2 among intravenous drug users (IVDU) and people originating from HTLV-1 highly endemic areas. Thus, in the most recent study from 2012, the prevalence of HTLV-2 among IVDU in Stockholm was 3.2%. However, much of the epidemiological data on HTLV in Sweden stems from studies conducted primarily between the 1990s and 2007, and the impact of migration to Sweden during the past 15 years has not been evaluated...
2024: AIDS Reviews
https://read.qxmd.com/read/38530117/ultrasensitive-response-explains-the-benefit-of-combination-chemotherapy-despite-drug-antagonism
#22
JOURNAL ARTICLE
Sarah C Patterson, Amy E Pomeroy, Adam C Palmer
Most aggressive lymphomas are treated with combination chemotherapy, commonly as multiple cycles of concurrent drug administration. Concurrent administration is in theory optimal when combination therapies have synergistic (more than additive) drug interactions. We investigated pharmacodynamic interactions in the standard 4-drug 'CHOP' regimen in Peripheral T-Cell Lymphoma (PTCL) cell lines and found that CHOP consistently exhibits antagonism and not synergy. We tested whether staggered treatment schedules could improve tumor cell kill by avoiding antagonism, using in vitro models of concurrent or staggered treatments...
March 26, 2024: Molecular Cancer Therapeutics
https://read.qxmd.com/read/38529384/composite-diffuse-large-b-cell-lymphoma-and-peripheral-t-cell-lymphoma-a-case-report-with-two-year-follow-up-and-literature-review
#23
Jiwei Gu, Juan Qian, Xin Cao
Composite lymphoma is an uncommon type of lymphoid malignancy, and those consisting of concurrent diffuse large B-cell lymphoma (DLBCL) and peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) in the same organ are rare. Here, we report a case of a 75-year-old male patient admitted to our emergency department with intestinal obstruction presenting with abdominal pain and vomiting. He underwent partial resection of the small intestine under general anesthesia, and subsequent histopathology confirmed the mass to be composite DLBCL and PTCL-NOS...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38528212/gamma-delta-t-cell-acute-lymphoblastic-lymphoma-leukemia-a-report-of-a-rare-entity
#24
JOURNAL ARTICLE
Giby V George, Maggie Kajstura, Andrew G Evans, Chauncey R Syposs
Gamma delta (γδ) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) is a rare, aggressive subtype of T-lymphoid leukemia that accounts for only 9-12% of all T-ALL cases. Herein, we report the case of an 8-year-old boy who presented with facial swelling, shortness of breath, and progressive cervical and axillary lymphadenopathy. Pathological examination, flow cytometry (Navios, Beckman Coulter ClearLLab 10C 10-color T-cell panel [containing FITC-labeled TCR γδ antibody]), chromosomal analysis, interphase FISH, and targeted DNA-based NGS (34-gene Illumina TruSeq Myeloid Panel) were performed...
March 25, 2024: Journal of Hematopathology
https://read.qxmd.com/read/38527847/-progress-in-treatment-of-primary-mediastinal-large-b-cell-lymphoma
#25
JOURNAL ARTICLE
L W Chen, J Y Li, L Fan
Primary mediastinal large B-cell lymphoma (PMBCL) is an aggressive B-cell lymphoma originating from the thymus, which has different clinical and biological characteristics from diffuse large B-cell lymphoma, NOS. PMBCL tends to occur in young women, usually presenting as a large anterior mediastinal mass. Most patients are in stage Ⅰ-Ⅱ at the time of presentation. There is no standard prognostic scoring system for PMBCL. Immunochemotherapy is commonly used in the treatment of PMBCL, but the optimal first-line treatment has not been determined, and the status of radiotherapy is controversial...
January 14, 2024: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
https://read.qxmd.com/read/38527562/enteric-associated-t-cell-lymphoma-in-a-mule
#26
Giovanna G de Souza, Zara A Lacerda, Fernanda B C de Moura, Isabeli J Contel, Shéron L de Oliveira, Lorena C Ferrari, Emanuel V P Apolonio, Juliana de M Alonso, Ana Liz G Alves, Noeme S Rocha
A 25-year-old female mule weighing 336 kg was referred with a history of lethargy, abdominal discomfort, anorexia, and constipation in the previous 24 hours. On admission, decreased intestinal borborygmi and distended small intestinal loops were detected by auscultation and rectal palpation, respectively. On rectal examination a firm, irregular surface, and pedunculated mass were detected in the middle-caudal region of the abdomen. Transrectal ultrasonography revealed the mass was highly vascularized with heterogeneous tissue density...
March 23, 2024: Journal of Equine Veterinary Science
https://read.qxmd.com/read/38525693/indolent-t-cell-lymphoproliferation-of-the-gastrointestinal-tract-an-evolving-disease-entity
#27
Luke Wang, Elaine Koh, Beena Kumar, Michael S Y Low
Background: Indolent T cell lymphoproliferation of the gastrointestinal tract is a novel entity recently added to the 2016 WHO classification of lymphoid neoplasms. Classically, these patients demonstrate an immunophenotype consistent with T cell proliferation and can be either CD4-positive or CD8-positive but with a low Ki67 index, highlighting the indolent nature of this disease compared to its more aggressive T cell lymphoma counterparts such as enteropathy-associated T cell lymphoma and monomorphic epitheliotropic intestinal T cell lymphoma...
March 22, 2024: Hematology Reports
https://read.qxmd.com/read/38525131/n-acetylcysteine-protects-against-diazinon-induced-histopathological-damage-and-apoptosis-in-renal-tissue-of-rats
#28
JOURNAL ARTICLE
Gaiqin Dong, Qingfeng Li, Chun Yu, Qing Wang, Danhua Zuo, Xiaozhong Li
Diazinon (DZN) is a member of organophosphorus insecticides that has cytotoxic effects on different organs. n-Acetyl cysteine (NAC) is a widely used antioxidant in clinical, in vivo and in vitro studies. We evaluated the protective role of NAC against DZN-induced toxicity in kidney tissue of Wistar rats. 30 male Wistar rats were divided into 5 groups of control, single dose of DZN, continuous dose of DZN, single doses of DZN + NAC and continuous doses of DZN + NAC. Kidney function test (blood urea nitrogen, creatinine and uric acid) was provided...
April 2024: Toxicological Research
https://read.qxmd.com/read/38525109/b-cell-pathway-dual-inhibition-for-systemic-lupus-erythematosus-a-prospective-single-arm-cohort-study-of-telitacicept
#29
JOURNAL ARTICLE
Lanlan Ji, Yan Geng, Xiaohui Zhang, Xuerong Deng, Zhibo Song, Meng Tan, Ying Tan, Chenxue Qu, Zhuoli Zhang
Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease associated with B-cell hyperactivity. Telitacicept is a transmembrane activator, calcium modulator, and cyclophilin ligand interactor-Fc fusion protein, which can neutralize both B-cell lymphocyte stimulator and a proliferation-inducing ligand. Patients with active SLE who received telitacicept were prospectively followed at month 1, 3, 6, 9, and 12 after telitacicept initiation. Thirty-seven participants were involved and followed for 6...
April 2024: MedComm
https://read.qxmd.com/read/38524018/t-cell-lymphoblastic-lymphoma-unveiling-as-superior-vena-cava-syndrome-in-a-19-year-old-male
#30
Rinkle Gemnani, Keyur Saboo, Rajvardhan Patil, Sunil Kumar, Sourya Acharya
Superior vena cava syndrome (SVCS) is a collection of signs and symptoms resulting from superior vena cava obstruction which is either partial or complete. SVCS is a rare clinical entity, often associated with various malignancies. T-cell lymphoblastic lymphoma (T-LBL) primarily of the mediastinum (thymus) is a rare and aggressive non-Hodgkin lymphoma that can lead to SVCS. We discuss the case of a 19-year-old male who arrived at our emergency department with symptoms of cough, breathlessness, and facial puffiness along with swelling in the right anterior mediastinum for two weeks suggestive of acute SVCS...
February 2024: Curēus
https://read.qxmd.com/read/38523995/nasal-type-natural-killer-t-cell-lymphoma-with-inaugural-testicular-presentation-in-a-young-patient
#31
Oumayma Mnafe, Eddou Hicham
Nasal-type natural killer/T-cell lymphoma is a rare non-Hodgkin's malignant lymphoma. A distinct clinicopathological entity associated with the Epstein-Barr virus, it typically presents with otorhinolaryngeal symptomatology. We report a rare case of a 24-year-old patient with nasal-type lymphoma with an atypical inaugural testicular presentation associated with the discovery of bilateral adrenal involvement.
February 2024: Curēus
https://read.qxmd.com/read/38523951/extramedullary-imaging-manifestations-of-leukemia-lymphoblastic-lymphoma-in-pediatrics-a-case-series
#32
Marcia Mejia, Mónica Royero Arias, Vanessa Santiago Pacheco, Jonathan Pimiento Figueroa
Leukemia is the most common childhood malignancy and often presents with nonspecific symptoms. Occasionally, it presents with extramedullary manifestations, which have been more frequent in cases of myeloid lineage or T cells. However, precursor B-cell leukemia/lymphoblastic lymphoma can also have extramedullary manifestations in some patients. Describing certain clinical features along with diagnostic imaging can establish a presentation pattern and suggest a diagnosis in the pediatric population. Herein, we present a series of four patients with extramedullary manifestations of B-cell lymphoblastic leukemia, describing their clinical imaging and histopathological characteristics...
February 2024: Curēus
https://read.qxmd.com/read/38521833/unbiased-serum-metabolomic-analysis-in-cats-with-naturally-occurring-chronic-enteropathies-before-and-after-medical-intervention
#33
JOURNAL ARTICLE
Maria Questa, Bart C Weimer, Oliver Fiehn, Betty Chow, Steve L Hill, Mark R Ackermann, Jonathan A Lidbury, Joerg M Steiner, Jan S Suchodolski, Sina Marsilio
Chronic enteropathies (CE) are common disorders in cats and the differentiation between the two main underlying diseases, inflammatory bowel disease (IBD) and low-grade intestinal T-cell lymphoma (LGITL), can be challenging. Characterization of the serum metabolome could provide further information on alterations of disease-associated metabolic pathways and may identify diagnostic or therapeutic targets. Unbiased metabolomics analysis of serum from 28 cats with CE (14 cats with IBD, 14 cats with LGITL) and 14 healthy controls identified 1,007 named metabolites, of which 129 were significantly different in cats with CE compared to healthy controls at baseline...
March 23, 2024: Scientific Reports
https://read.qxmd.com/read/38520941/htlv-1-associated-myelopathy-tropical-spastic-paraparesis-ham-tsp-case-based-discussion-of-risk-factors-clinical-and-therapeutic-considerations
#34
REVIEW
Lea Saab, Daniel DiCapua, Adeel S Zubair
HTLV-1 is a retrovirus virus that infects CD4+ T cells. Most people with HTLV-1 infection remain asymptomatic but some may develop conditions such as HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP) or adult T-cell leukemia/lymphoma. HAM/TSP is characterized by progressive spasticity and weakness of the lower extremities, as well as loss of bladder control and sensory disturbances. The risk of developing HAM/TSP is associated with the duration of infection and the proviral load. There is currently no cure for the disease but medications can help manage symptoms and slow the progression of the disease...
March 19, 2024: Journal of the Neurological Sciences
https://read.qxmd.com/read/38520011/clinicopathological-and-molecular-genetic-alterations-in-monomorphic-epitheliotropic-intestinal-t-cell-lymphoma-of-the-small-intestine
#35
JOURNAL ARTICLE
Bing Zhou, Min Guo, Xiaohua Li, Ting Duan, Lizi Peng, Hua Hao
BACKGROUND: Small intestinal monomorphic-epitheliotropic intestinal T-cell lymphoma (MEITL) is a rare aggressive T-cell lymphoma originating in the gastrointestinal tract. This study aimed to investigate the clinicopathological features, immunophenotypes, and molecular genetic changes of MEITL. METHODS: The clinicopathological data for three patients with surgically resected MEITL of the small intestine were collected. Next, immunohistochemical labeling, Epstein-Barr virus (EBV) in situ hybridization, assessment of clonal rearrangement of T-cell receptor (TCR) genes, and next-generation sequencing (NGS) were performed...
March 23, 2024: European Journal of Medical Research
https://read.qxmd.com/read/38519055/molecular-assessment-of-intratumoral-immune-cell-subsets-and-potential-mechanisms-of-resistance-to-odronextamab-a-cd20%C3%A3-cd3-bispecific-antibody-in-patients-with-relapsed-refractory-b-cell-non-hodgkin-lymphoma
#36
JOURNAL ARTICLE
Jurriaan Brouwer-Visser, Nathalie Fiaschi, Raquel P Deering, Kamil J Cygan, Darius Scott, Se Jeong, Lauren Boucher, Namita T Gupta, Suraj Gupta, Christina Adler, Max S Topp, Rajat Bannerji, Johannes Duell, Ranjana H Advani, Dina M Flink, Aafia Chaudhry, Gavin Thurston, Srikanth R Ambati, Vladimir Jankovic
BACKGROUND: Patients with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL) have a significant need for effective treatment options. Odronextamab is an Fc-silenced, human, CD20×CD3 bispecific antibody that targets CD20-expressing cells via T-cell-mediated cytotoxicity independent of T-cell/major histocompatibility complex interaction. Phase I results in patients with R/R B-NHL demonstrated that odronextamab monotherapy could achieve deep and durable responses with a generally manageable safety profile (ELM-1; NCT02290951)...
March 21, 2024: Journal for Immunotherapy of Cancer
https://read.qxmd.com/read/38517235/phase-ii-study-of-the-novel-antifolate-agent-pralatrexate-in-combination-with-the-histone-deacetylase-inhibitor-romidepsin-for-the-treatment-of-patients-with-mature-t-cell-lymphoma
#37
JOURNAL ARTICLE
Yun Kyoung Ryu Tiger, Salvia Jain, Stefan K Barta, Seda Tolu, Brian Estrella, Ahmed Sawas, Jennifer K Lue, Mark M Francescone, Barbara Pro, Jennifer E Amengual
Previously, we conducted a Phase I study of the combination of pralatrexate and romidepsin in patients with relapsed/refractory (R/R) lymphomas and subsequently conducted a multicenter Phase II study in patients with untreated or R/R mature T cell lymphomas (MTCL). Patients received pralatrexate 25 mg/m2 and romidepsin 12 mg/m2 every 2 weeks. Fourteen patients were evaluable for efficacy. Overall response rate was 35.7% with CR in 14.3% and disease control in 50%. The mDOR was 8.2 months, mPFS was 3...
March 22, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38517059/gamma-delta-t-cell-lymphoma-of-the-central-nervous-system-a-case-report-and-review-of-the-literature
#38
JOURNAL ARTICLE
Alexa T Andre, Meagan Chambers, Daniel E Sabath
Primary T-cell lymphoma (TCL) of the central nervous system (CNS) is a rare and potentially aggressive entity. We describe a case of TCL presenting in the basal ganglia with γδ receptor expression and a remarkably aggressive clinical course. To the best of our knowledge, this is the fifth reported case of γδ TCL presenting in the CNS. We review existing literature, including the previously reported cases of γδ TCL of the CNS. In our case, a 69-year-old male presented with acute onset dysarthria and right-sided weakness, with initial imaging concerning for stroke...
March 22, 2024: Clinical Neuropathology
https://read.qxmd.com/read/38516299/car-designs-for-solid-tumors-overcoming-hurdles-and-paving-the-way-for-effective-immunotherapy
#39
JOURNAL ARTICLE
Yuanbin Cui, Mintao Luo, Chuanyuan Gu, Yuxian He, Yao Yao, Peng Li
Chimeric antigen receptor T cell (CAR-T) therapy has revolutionized immunotherapy by modifying patients' immune cells genetically. By expressing CARs, these modified cells can specifically identify and eliminate tumor cells. The success of CAR-T therapy in hematological malignancies, such as leukemia and lymphoma, has been remarkable. Numerous studies have reported improved patient outcomes and increased survival rates. However, the application of CAR-T therapy in treating solid tumors faces significant challenges...
October 31, 2023: Biophysics Reports
https://read.qxmd.com/read/38513135/genomic-profiling-of-mycosis-fungoides-identifies-patients-at-high-risk-of-disease-progression
#40
JOURNAL ARTICLE
Léa Fléchon, Inès Arib, Ankit K Dutta, Lama Hasan Bou Issa, Romanos Sklavenitis-Pistofidis, Remi Tilmont, Chip Stewart, Romain Dubois, Stéphanie Poulain, Marie-Christine Copin, Sahir Javed, Morgane Nudel, Doriane Cavalieri, Guillaume Escure, Nicolas Gower, Paul Chauvet, Nicolas Gazeau, Cynthia Saade, Marietou Binta Thiam, Aïcha Ouelkite-Oumouchal, Silvia Gaggero, Émeline Cailliau, Sarah Faiz, Olivier Carpentier, Nicolas Duployez, Thierry B Idziorek, Laurent Mortier, Martin Figeac, Claude Preudhomme, Bruno Quesnel, Suman Mitra, Franck Morschhauser, Gad Getz, Irene M Ghobrial, Salomon Manier
Mycosis fungoides (MF) is the most prevalent primary cutaneous T-cell lymphoma, with an indolent or aggressive course and poor survival. The pathogenesis of MF remains unclear, and prognostic factors in the early stages are not well-established. Here, we characterized the most recurrent genomic alterations using whole-exome sequencing of 67 samples from 48 patients from Lille University Hospital (France), including 18 sequential samples drawn across stages of the malignancy. Genomic data were analyzed on the Broad Institute's Terra bioinformatics platform...
March 21, 2024: Blood Advances
keyword
keyword
69325
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.